SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-22-013598 to Hero Technologies Inc. (HENC) (CIK 0001324736)

Hero Technologies Inc. (HENC) (CIK 0001324736)
Date: Dec. 16, 2022 · CIK: 0001324736 · Accession: 0000000000-22-013598

AI Filing Summary & Sentiment

File numbers found in text: 333-268717

Date
December 16, 2022
Author
Not clearly detected
Form
UPLOAD
Company
Hero Technologies Inc. (HENC) (CIK 0001324736)

Letter

United States securities and exchange commission logo December 16, 2022 Gina Serkasevich Chief Executive Officer Hero Technologies Inc. 8 The Green Suite 4000 Dover, DE 19901 Re:Hero Technologies Inc. Registration Statement on Form S-1 Filed December 8, 2022 File No. 333-268717 Dear Gina Serkasevich: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William T. Hart

Show Raw Text
United States securities and exchange commission logo
December 16, 2022
Gina Serkasevich
Chief Executive Officer
Hero Technologies Inc.
8 The Green Suite 4000
Dover, DE 19901
Re:Hero Technologies Inc.
Registration Statement on Form S-1
Filed December 8, 2022
File No. 333-268717
Dear Gina Serkasevich:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       William T. Hart